Cadence Pharmaceuticals Inc (CADX)
Quote as of 10:12 AM ET 07/29/2010 (NASDAQ GM)
| Last: 7.33 |
Change: $0.02 |
Percent Change: 0.27 |
Volume: 5,815 |
Cadence Pharmaceuticals, Inc. is a biopharmaceutical company focused on in-licensing, developing and commercializing product candidates for use in the hospital setting. The Company has rights to one product candidate, Ofirmev, an intravenous formulation of acetaminophen for the management of pain and reduction of fever in adults and children. The Company has in-licensed the exclusive United States and Canadian rights to Ofirmev from Bristol-Myers Squibb Company (BMS), which sells this product candidate in Europe and other markets for the treatment of acute pain and fever under the brand name Perfalgan. Acetaminophen is available in over 600 combination and single-ingredient prescription and over-the-counter medicines, including tablet, caplet, orally-dosed liquid suspension, powder and suppository forms for both adults and children. The Company focuses on distributing Ofirmev primarily to drug wholesalers, who distributes the product to hospital pharmacies and other institutions.
Latest News
11:52:00 AM 7/28/2010
Oxford Finance Corporation Leads $30 Million Secured Loan Facility for Cadence Pharmaceuticals
ALEXANDRIA, Va., July 28, 2010 /PRNewswire via COMTEX/ --
Oxford Finance Corporation, a subsidiary of Sumitomo Corporation, today announced that it was the lead lender for a $30 million credit facility provided to Cadence Pharmaceuticals. Silicon Valley Bank and GE Financial Services, Inc. also participated in the loan agreement. This infusion of capital will support the company's potential launch of their investigational product candidate, OFIRMEV(TM), an intravenous formulation of acetaminophen that is currently marketed in Europe for the treatment of acute pain and fever.
4:00:00 PM 6/21/2010
Cadence Pharmaceuticals Signs Option Agreement to Acquire Incline Therapeutics
SAN DIEGO, June 21, 2010 /PRNewswire via COMTEX/ --
Cadence Pharmaceuticals, Inc. (CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that it has signed an agreement providing Cadence with an exclusive option to acquire Incline Therapeutics, Inc., a privately held specialty pharmaceutical company.
4:45:00 PM 5/14/2010
Cadence Pharmaceuticals Announces OFIRMEV(TM) NDA Action Date of November 4, 2010
SAN DIEGO, May 14, 2010 /PRNewswire via COMTEX/ --
Cadence Pharmaceuticals, Inc. (CADX) announced today that the U.S. Food and Drug Administration (FDA) has classified the OFIRMEV(TM) (acetaminophen) injection New Drug Application (NDA) resubmission as a complete Class 2 response to the FDA's February 10, 2010 action letter and assigned a new Prescription Drug User Fee Act (PDUFA) action date of November 4, 2010.
4:01:00 PM 5/6/2010
Cadence Pharmaceuticals Reports First Quarter 2010 Financial Results
SAN DIEGO, May 6, 2010 /PRNewswire via COMTEX/ --
Cadence Pharmaceuticals, Inc. (CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today reported financial results for the first quarter ended March 31, 2010.
9:00:03 AM 5/5/2010
Analysis Group Hosts Panel at 2010 BIO International Convention
CHICAGO, May 05, 2010 (BUSINESS WIRE) --
Analysis
Group will bring together leaders in the biopharmaceutical field to
discuss and debate licensing, reimbursement, and commercial strategies
for the increasingly competitive global biopharmaceutical market at the
2010 BIO International Convention held May 3-6, 2010 in Chicago, Ill.
The firm's participation at this Convention highlights its depth and
breadth of experience in strategic issues of critical importance to
diverse stakeholders across the biopharmaceutical industry.